Abridge carries a $6.69 billion mark on trials showing its scribe saves 22 minutes a day
The independent trials have landed next to the expansion metrics: 22 minutes a day is what a health system can actually count. That caps the per-encounter price and moves the value to clinical content and workflow, where Wolters Kluwer and Doximity trade.
Richard Tang · 2 min read
Abridge$6.69B — Abridge, private, latest valuation $6.69B spent six weeks selling access: 300 of the largest US health systems, more than 100 million patient-clinician conversations expected this year, an enterprise framework across all eight University of Texas health institutions, and September's selection under the VA's ambient-AI contract, a five-year $775.72 million ceiling shared across competing vendors 23. What landed alongside it is the first independent measurement of what that access buys a clinician: 22 minutes a day 1. That gap, priced against Abridge's $6.69 billion private mark, is the whole valuation question 5.
What the trials actually measured
The randomised evidence is the new fact this month. A 24-week trial across 66 practitioners in Wisconsin and Illinois, using Abridge in production, found note time down 0.36 hours a day, no statistically significant gain in professional fulfilment, and a cut in out-of-hours work that stopped being significant once the highest 3% of observations were dropped 1.
A UCLA head-to-head in NEJM AI found the same shape: Nabla cut note-writing time 9.5%, Microsoft's−2.35% — Microsoft, down 2.35 percent today DAX 1.7% was not significant, and clinicians used the tools in only about a third of eligible visits 1. A Veterans Health Administration evaluation, 30 blinded raters scoring five standardized cases, put human note takers above 11 AI scribes in all five 1.
Ambient documentation and billing AI took three quarters of 2025 healthcare-AI money
- Estimate
Data
| Value | |
|---|---|
| Ambient documentation | $600M |
| Coding and billing automation | $450M |
| Rest of 2025 healthcare AI (estimate) | $350M |
Twenty-two minutes caps the per-encounter price
Twenty-two minutes is real work lifted from a clinician's day, which is why deployments keep growing. But it is a benefit a buyer can count, and a benefit a buyer can count is a price a buyer can negotiate. Volume metrics justify the funnel; they do not set the margin.
Abridge's own answer is pre-bill claim review, its first product in the mid-revenue cycle, launched this month on October 9, which we covered then 5. Doximity+0.45% — Doximity, up 0.45 percent today is making the same move from the other side, bundling Scribe, Ask and Dialer into one assistant 4.
Own the content, not the scribe
That is why the content layer is the position to hold. UpToDate's evidence base is now embedded in AI tools from Epic, Abridge, Doximity and Suki, and Doximity's clinical AI tools already sit in more than 165 health systems 4. Wolters Kluwer is the listed way to own it; Doximity is the public comparable.
One caveat: the licensing is contestable, because the platforms embedding UpToDate could eventually build or buy their own evidence layer. But peer-reviewed clinical judgment is far harder to re-derive than a fluent draft, and the VHA's five-for-five result shows exactly how hard.
The mark to watch, then, is $6.69 billion against 22 minutes. The next clock is concrete: what the first VA task orders are worth, and when they land.
Get Health by email, free
AI in medicine, pharma and biotech. In our daily email, every weekday.
